Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
PMID: 35001501
2022
Journal of the International AIDS Society
Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,
HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
PMID: 34762770
2021
Journal of the International AIDS Society
Table: L234I
Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan.
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Result: This was followed by G190A/S/E/G that occurred in 55 (30.2%) of the patients, P236L mutation occurred in 2 (1.1%) and L234I that occurred in only 4 (2.2%) of the participants.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
PMID: 32030406
2020
The Journal of antimicrobial chemotherapy
Abstract: METHODS: We used the WHO 2009 list to investigate the prevalence of NNRTI, NRTI and PI TDR, in treatment-naive HIV-1-infected patients, adding mutations E138A/G/K/Q/R, V106I, V108I, V179L, G190Q, H221Y, F227C/L/V, M230IDR, L234I, P236L and Y318F in RT.
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Mutations that emerged secondary to V106A/M included F227L/C/V or L234I.
Introduction: The double mutant viruses V106A/L234I (subtype B) and V108I/L234I (subtype A) eventually acquired a third mutation to give triple mutant viruses V106A/L234I/F227L (subtype B) and V108I/L234I/V106A(I) that both conferred over 150-fold decreases in DOR susceptibility.
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
PMID: 31976534
2020
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus
Abstract: The following mutations were considered as resistance mutations: V106A/M, V108I, Y188L, G190S, F227C/L/V, M230I/L, L234I, P236L, K103N + Y181C, K103N + P225H and K103N + L100I.
HIV mutation literature information.
PMID: 
2022
Journal of the International AIDS Society
Browser Board
Co-occurred Entities
Filtrator
ViMRT